Insilicos, Collaborators Publish Results of Human Cardiovascular Study
Seattle, 12 July 2010 - Insilicos and collaborators at the University of Washington have published results showing that the company's biomarker platform is a rich source of information on human cardiovascular health. The paper correlates changes in high-density lipoprotein (HDL) particles with cardiovascular disease.
The paper in the journal Clinica Chimica Acta is authored by Insilicos chief scientiest Dr. Bryan Prazen, UW scientist Dr. Tomas Vaisar, and others. The paper describes changes in the protein composition of HDL particles that correlate with cardiovascular disease, as well as responses to treatment.
"We are excited to share this work with the research community," said Dr. Prazen. "These results demonstrate the potential of lipoprotein complexes as a rich source of biomarkers and diagnostic insight."
The article is cited as Clin Chim Acta. 2010 Jul 4;411(13-14):972-9), Pubmed 20307520
Insilicos LLC is a biomarker discovery and diagnostic development company, concentrating on cardiovascular disease.
For more information, visit the Insilicos web site www.insilicos.com or contact Insilicos at info@insilicos.com. 'Insilicos' 'PreClue," and 'Life Science Software' are trademarks of Insilicos LLC.
